NCT05671900View on ClinicalTrials.gov

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Non-muscle-invasive Bladder Cancer
Interventions
DRUG

Gemcitabine 1000 mg, Docetaxel 37.5g

6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.

Trial Locations (1)

10000

University Hospital Centre Zagreb, Zagreb

All Listed Sponsors
lead

Clinical Hospital Centre Zagreb

OTHER